Poster Hall
Sponsored by AbbVie Medical Affairs
Conference Perspectives
View all perspectives
Peter Nash drpnash
3 months 1 week ago
EULAR Abstract Archive
POS0894 (2024)
SAFETY OF UPADACITINIB ACROSS RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS, AND AXIAL SPONDYLOARTHRITIS ENCOMPASSING 15,000 PATIENT-YEARS OF CLINICAL TRIAL DATA
Reassuring 15000 pt yrs f/u RA PsA AS https://t.co/XWnzuVMlbn @RheumNow #EULAR2024
Peter Nash drpnash
3 months 1 week ago
lets put this bed now @RheumNow #EULAR https://t.co/r0SVoOk47O
Peter Nash drpnash
3 months 1 week ago
EULAR Abstract Archive
OP0283 (2024)
LONG-TERM EFFICACY TOCILIZUMAB AFTER ULTRA-SHORT GC TO TREAT GCA: 3 Yr FOLLOW-UP OF THE GUSTO TRIAL
3 day GC pulse immediate 12 mths Toci 85% drug free remission at 4 yrs! https://t.co/XWnzuVMlbn @RheumNow #EULAR2024
Peter Nash drpnash
3 months 1 week ago
EULAR Abstract Archive
RISK OF PsA IN PATIENTS WITH PsO UNDERGOING bDMARDs GLOBAL POPULATION STUDY (TRINETX)
870,000 PsO pts without PsA treated with bDMARDS - Il12/23i and Il23i. 30-37% lower PsA developed than comparators https://t.co/XWnzuVMlbn @RheumNow #EULAR2024
Peter Nash drpnash
3 months 1 week ago
EULAR Abstract Archive
OP0031 (2024)
COMPARATIVE ANALYSIS OF TNF INHIBITORS & IL17 INHIBITORS IN PSORIATIC ARTHRITIS: CARDIOVASCULAR OUTCOMES signif absolute risk diff 3 % ischaemic heart disease 2 % heart failure TNFi vs IL17i https://t.co/fNIiMt4caL. @RheumNow #EULAR2024
Dr. Antoni Chan synovialjoints
3 months 1 week ago
Zoe @ZoeClarkOsteo from @NASSexercise @NASSchiefexec presenting her work from the Your SpAce self-management programme which covers topics on pain, fatigue, flares and much more #EULAR2024 @RheumNow https://t.co/q81JDHu7Oj
Peter Nash drpnash
3 months 1 week ago
Grappa « difficult to treat and complex to manage» PsA meeting - SLR, Patient & rheumo survey, working on definition eg - fail 1 csDMARD & 2 bDMARDs different MOA @RheumNow #EULAR2024
Peter Nash drpnash
3 months 1 week ago
CAR-T - autologous vs allogenic , need for full induction , safety of retreatment, CAR-T lymphoma/leukaemia, cost, ideal candidate ? @RheumNow #EULAR2024
Peter Nash drpnash
3 months 1 week ago
opposing point of view to previous post @RheumNow #EULAR2024 https://t.co/T72r8kXF1j
Md Yuzaiful Md Yusof Yuz6Yusof
3 months 1 week ago
#EULAR2024 POS1325 Childhood onset #lupus is often more severe with high mortality rate. Similar to findings in adults, 2 cSLE patients with refractory disease including failure to CyC, RTX & PLEX responded to CD19 CAR T cells with similar short term safety profile @RheumNow https://t.co/YD2arjxcso
Peter Nash drpnash
3 months 1 week ago
lanalumab (anti-baff) LTE 1/3 to 1/2 LLDAS/DORIS remission at 52 wks, reduction autoabs etc - looking very promising @RheumNow #EULAR2024
Aurelie Najm AurelieRheumo
3 months 1 week ago
Frank Buttgereit discusses potential reason for ceiling effect in RA and questions why we don’t use more combination therapy in RA (including low dose of of GC), using the example of Hypertension guidelines
Is long term low dose GC in RA really a desirable option?
@RheumNow… https://t.co/Nc7lldN7Nd https://t.co/63K96uuhKG
Dr. Antoni Chan synovialjoints
3 months 1 week ago
Tips to help in self-management. Procrastination is a huge barrier to self-management. Delegate and prioritise #EULAR2024 Andrea Marques @RheumNow https://t.co/SbQgOMwqL0
Mrinalini Dey DrMiniDey
3 months 1 week ago
Steroids are often started before pts see a rheumatologist
This associates with long-term low-dose steroid use
Need better collaboration between referrers and rheum to reduce this avoidable steroid burden
POS0137 @RheumNow #EULAR2024
Md Yuzaiful Md Yusof Yuz6Yusof
3 months 1 week ago
#EULAR2024 POS0436 Another benefit of T2T to achieve remission by using less NSAIDs, lower GC, earlier use of SFZ, HCQ and TNF-i = shorter Time to Pregnancy from conception in #RA women (median 84 days) vs without pre-counselling & T2T (196 days) @RheumNow https://t.co/2ZpDLmPVt0
